Inactive Instrument

Ligand Pharmaceuticals Inc. Share Price OTC Bulletin Board

Equities

US53220K1815

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Ligand Pharmaceuticals Inc.
Sales 2024 * 138M 11.49B Sales 2025 * 157M 13.12B Capitalization 1.51B 126B
Net income 2024 * 92M 7.67B Net income 2025 * 50M 4.17B EV / Sales 2024 * 11 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 9.61 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
26.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.65%
More Fundamentals * Assessed data
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease MT
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults CI
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views MT
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83 MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024 CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference CI
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics CI
More news
Managers TitleAgeSince
Chief Executive Officer 63 01/07/01
Director of Finance/CFO 53 01/22/01
President 49 06/15/06
Members of the board TitleAgeSince
Chairman 74 01/03/01
Director/Board Member 74 01/11/01
Director/Board Member 64 04/08/04
More insiders
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Related indices
More about the company